http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
전이성 유방암에 대한 Cyclophosphamide , Adriamycin , Methotrexate , 5 - FU ( CAMF ) 4 제 복합화학요법
김시영(Si Young Kim),김흥태(Heung Tae Kim),강윤구(Yoon Koo Kang),서철원(Cheol Won Suh),방영주(Yung Jue Bang),김노경(Noe Kyeong Kim),이건욱(Kun Uk Lee),최국진(Kuk Jin Choe),김수태(Soo Tae Kim) 대한내과학회 1988 대한내과학회지 Vol.34 No.6
N/A Between November, 1984 and January, 1987 32 patietns with metastatic breast cancer were treated with CAMF combination chemotherapy. Median age waa 45. Fourteen patients had prior chemotherapy and 2 patients had prior endocrine therapy. The menopausal status was as follows; 13 patients were postmenopausal, 19 premenopausal. The performance status was grade 0 to 1 (ECOG) in 13 patients, 2 in 12 and 3 in 7. Treatment was cyclophosphamide 750mg/m iv, day 1, adriamycin 30mg/㎟ iv, day 1; methotrexate 40mg/㎟ iv, day 8, and 5-FV 500 mg/㎟ iv, day 9. The treatment was recycled every 4 weeks until the progression of disease. Among 32 patients, 18 (56%) achived responses (1 CR and 17 RP), Median duration of response was 9 months. Median survival for all patients was 12 months. Toxicity was as follows; leukopenia 56 %, thrombocytopenia 15%, N/V 63%. No treatmentrelated death was observed during the treatment. It was concluded that CAMF combination chemotherapy is not superior to other cornbination chemotherapy regiments, and myelosuppression is a major dose-limiting toxicity.
대장암에 대한 5 - Flurouracil 지속주입 및 Cisplatin ( FP ) 복합화학요법의 치료효과
서철원(Cheol Won Suh),김시영(Si Young Kim),방영주(Yung Ju Bang),김노경(Noe Kyeong Kim),박재갑(Jae Gahb Park),이건욱(Kuhn Uk Lee),홍성국(Sung Kuk Hong),최국진(Kuk Jin Choe),김수태(Soo Tae Kim),하성환(Sung Hwan Ha),박찬일(Chan Il Park) 대한내과학회 1988 대한내과학회지 Vol.35 No.4
N/A Between August 1986 and February 1988, 60 patients with metastatic or recurrent colorectal cancer were treated with a combination chemotherapy consisting of 5-fluorouracil, 1,000 mg/m² iv continuous infusion over 12 hours on Days 1-5 and cisplatin,.60 mg/m² iv on Day 1; cycled every 3 weeks, Among 36 patients with measurable disease, none achieved complete response and 9 (25%) had partial responses, thus this combination chemotherpay regimen showed modest action on the advanced colorectal cancer. The median duration of response was 20 weeks. Median survival was 52 weeks for all patients who could be evaluated for response and/or toxicity; 61 weeks for patients with response, 48 weeks for those with stable disease and 17 weeks for those with progressive disease. In the analysis of the response according to the various pretreatment characteristics of the patients, those without a history of previous anticancer chemotherapy showed response rate of 36% which is better than 7% for those with prior chemotherapy. The patients with metastatic sites in the liver had a response rate of 47%, which is significantly better than 7 96 for those with metastatic site in the lung and 0% for those with any other sites of metastasis. Toxicity was common, but generally mild to moderate and rapidly reversible.